Amyris : John Melo, President & CEO, Amyris, Inc - Form 8-K
January 13, 2022 at 06:11 am EST
Share
John Melo, President & CEO, Amyris, Inc.
…
I'd like to call out on the forward-looking statements on Slide 2. During today's presentation, I will be sharing preliminary unaudited revenue numbers for 2021.
…
With reference to slide 15: Our fourth quarter revenue will be around $65 million; that is all underlying revenue. And then for 2021 as a whole, we believe we expect to exceed $340 million in total revenue for the year…We're glad that we're able to execute with all the headwinds facing supply chain and the new variant around the virus, being able to still execute and exceed what was the analyst consensus both for the year and for the quarter.
…
With reference to slide 16: We had a very strong 2021. Our cumulative annual growth rate for the last 3 years is a little over 120%.
Relevant slides from Amyris' presentation at the J.P. Morgan Healthcare Conference on January 12, 2022:
Attachments
Original Link
Original Document
Permalink
Disclaimer
Amyris Inc. published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 11:10:08 UTC.
Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Companyâs sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.
AMYRIS, INC. 
